Enzo patent win
This article was originally published in The Gray Sheet
Executive Summary
Enzo Biochem managed to fend off Siemens' patent interference claim against the small biotech's pending nucleic acid signal amplification patent, which Enzo suggests forms an important basis for an already existing $100 million segment of the diagnostics market. Enzo announced May 17 that the U.S. Patent and Trademark Office had denied Siemens' request for a rehearing on whether the inventions in a DNA testing patent now owned by the diversified company were made prior to the very similar inventions in Enzo's patent. USPTO ruled in February that the substance of Enzo's claims came first. Enzo, still waiting on final approval of its patent, says the claims address aspects of Siemens' Versant branched DNA assays, among other companies' tests on the market. Enzo would not comment on plans to pursue damages from Siemens or other planned legal or licensing actions
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.